ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

This study has been completed.

Sponsors and Collaborators: Baylor College of Medicine
The Methodist Hospital System
Texas Children's Hospital
Center for Cell and Gene Therapy
Information provided by: Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00048412
  Purpose
  1. To assess the treatment related mortality of allogeneic stem cell transplantation with non-myeloablative therapy incorporating the lymphodepleting MAb CAMPATH-1H, in patients with hematological diseases and renal cell carcinoma not eligible for conventional (myeloablative) therapy.
  2. To assess the time to engraftment and incidence of graft failure in patients receiving this transplant regimen.
  3. To assess the safety, pharmacokinetics and immunologic activity of CAMPATH-1H when used as part of a subablative conditioning regimen.

Condition Intervention Phase
Myelodysplastic Disorders
Leukemia
Multiple Myeloma
Plasma Cell Dyscrasia
Lymphoproliferative Disorders
Drug: FLUDARABINE
Drug: CAMPATH 1H
Drug: FK50
Procedure: Stem Cell Collection and Infusion
Phase I
Phase II

Genetics Home Reference related topics:   aceruloplasminemia    hemophilia   

MedlinePlus related topics:   Cancer    Leukemia, Adult Acute    Leukemia, Adult Chronic    Leukemia, Childhood    Multiple Myeloma   

ChemIDplus related topics:   Fludarabine    Fludarabine monophosphate    Alemtuzumab    Campath   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:   Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancy, Using MHC Identical or Near Identical Donors and Sub-Myeloablative Conditioning With CAMPATH 1H (DIMSUM)

Further study details as provided by Baylor College of Medicine:

Estimated Enrollment:   40
Study Start Date:   June 2000

Detailed Description:

This is a two arm study in which outcomes will be assessed independently in recipients of HLA matched sibling transplants and recipients of unrelated or mismatched family donor transplants, although both groups will receive identical treatments.

The following will be given to the patient after admission:

Day - 6: Total body irradiation

Day - 5 to - 2: Fludarabine and Campath 1H

Day - 1: Day of rest

Day 0: Stem cell transplant (infusion)

  Eligibility
Ages Eligible for Study:   up to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion criteria

  1. Diagnosis of myelodysplastic disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative disorders (Non-Hodgkin Lymphoma, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia and Hodgkins Disease) or Renal Cell Carcinoma.
  2. Conditions that increase treatment related mortality (need one or more to be eligible):

    1. Greater to or equal to 50 years of age.
    2. EF of less than 45%
    3. DLCO less than 50% of FEV1 50-75% of predicted value.
    4. Diabetes Mellitus
    5. Renal Insufficiency (but creatine clearance not less than 25ml/min).
    6. Prior recent history of systemic fungal infection.
    7. 3rd or greater remission of AML or ALL
    8. More than 1 year of diagnosis (CML or Myeloma patients)
    9. Multiple types of treatment regimens. (equal to or more than 3)
    10. Prior autologous or allogeneic stem cell transplantation.
    11. Significant grade III or IV neurologic or hepatic toxicity from previous treatment.
    12. No matched sibling donor.
  3. Available healthy donor without any contraindications for donation. 5/6 or 6/6 related donor. 5/6 or 6/6 unrelated donor (molecular typing for DRB1)
  4. Patient and/or responsible person able to understand consent.
  5. Age between birth and 70 years.
  6. For women of childbearing potential, negative pregnancy test.

Exclusion criteria

  1. Patient is pregnant, lactating or unwilling to use contraceptives
  2. HIV positive patient
  3. Uncontrolled intercurrent infection
  4. Refractory AML, or ALL
  5. Untreated Blast Crisis for CML
  6. Uncontrolled High-grade lymphoproliferative disease/lymphoma.
  7. Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater)
  8. Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater)
  9. Hemodialysis dependent
  10. Active Hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3 x normal.
  11. Unstable Cerebral vascular disease and recent hemorrhagic stroke (less than 6 months)
  12. Active CNS disease from hematological disorder.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048412

Locations
United States, Texas
Texas Children's Hospital    
      Houston, Texas, United States, 77030
The Methodist Hospital    
      Houston, Texas, United States, 77030

Sponsors and Collaborators
Baylor College of Medicine
The Methodist Hospital System
Texas Children's Hospital
Center for Cell and Gene Therapy

Investigators
Principal Investigator:     George Carrum, MD     Baylor College of Medicine    
  More Information


Study ID Numbers:   H8714, DIMSUM
First Received:   October 30, 2002
Last Updated:   April 9, 2007
ClinicalTrials.gov Identifier:   NCT00048412
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Immunoproliferative Disorders
Blood Protein Disorders
Hematologic Diseases
Blood Coagulation Disorders
Vascular Diseases
Paraproteinemias
Fludarabine monophosphate
Hemostatic Disorders
Multiple Myeloma
Leukemia
Lymphatic Diseases
Hemorrhagic Disorders
Multiple myeloma
Alemtuzumab
Fludarabine
Lymphoproliferative Disorders
Neoplasms, Plasma Cell

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Disease
Immune System Diseases
Antineoplastic Agents
Therapeutic Uses
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers